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The 14
th annual gathering of the Signal Transduction
Society (STS; http://www.sigtrans.de) brought together
scientists from eleven different countries in Weimar,
Germany. The conference focus topic for 2010 was ’Sig-
nal Transduction, Drug Discovery and Design’.
Accordingly, the molecularly targeted interference
with disease-driving signal transduction pathways was a
major theme of many presentations. From these it
became apparent that, in addition to the by now almost
‘classical’ blockers of kinases, inhibitors of protein - pro-
tein interactions are beginning to make their way
towards the center stage.
It was therefore very timely that the newly introduced
Honorary Medal of STS and CCS was presented to Prof.
Tony Pawson, one of the founding fathers of protein -
protein interaction research in cell signaling ‘for the dis-
covery of protein interaction domains and elucidating
their essential roles in the transmission of cellular
signals’.
Tony and his team discovered the Src Homology 2
(SH2) domains in the mid 1980s as conserved and func-
tionally relevant regions in cytoplasmic tyrosine kinases
[1,2]. From there, it took almost another five years until
the ability of SH2 domains to bind to certain tyrosine
phosphorylated proteins was reported by three groups,
initially at the 6
th Oncogene Meeting (26-30 June 1990;
Frederick, MD, USA) [3-5].
From then on this research field expanded massively
and Tony Pawson has been repeatedly leading the way,
conceptually and experimentally. At present over 200
posttranslational protein modifications and over 100
‘reader’ domains for these modifications have been iden-
tified in the human proteome.
One of several conference highlights in this area was
the presentation of multiple novel crystal structures and
an anti-oncogenic inhibitor of BET subfamily bromodo-
mains by Panagis Filippakopoulos et al. from the Oxford
branch of the Structural Genomics Consortium [6]. This
first example of a specific inhibitor for a chromatin
modification-reading protein interaction domain with in
vivo activity is expected to add further momentum to
the current shift of interests in the pharmaceutical sec-
tor towards the realm of epigenetic processes.
Another important message emerged, for example,
from the presentation of Toby Gibson (EMBL, Heidel-
berg): it is time for signal transduction researchers to
say ‘Goodbye’ to simple cascade models, and also to
mathematical equations based on solution phase chem-
istry, which are often useless or misleading if one wants
to quantitatively describe the actions of signal transduc-
tion proteins that act as parts of large multi-protein
complexes [7]. Moreover, a bit like the internet, the sig-
nal transduction systems of cells appear to have no true
master controllers, presumably giving them greater
robustness against various forms of assault and also pro-
viding adaptability to new environmental challenges that
may not be as feasible or effective with more hierarchi-
cal networks.
Clearly, signal transduction research has come a long
way since its early beginnings, but new challenges are
readily awaiting attention, especially with respect to
understanding higher levels of signal processing, signal
fine-tuning, and also the elucidation of spatio-temporal
details and mechanisms of action of physiological signal-
ing events, for example by high resolution imaging in
real-time. Correspondence: stephan.feller@imm.ox.ac.uk
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